

THE ROLE OF THE -160 C/A SINGLE NUCLEOTIDE POLYMORPHISM IN THE CDH1
GENE AND E-CADHERIN EXPRESSION IN ETIOLOGY, PROGRESSION, AND
SURVIVAL IN INVASIVE BREAST CANCER

by

Sandra L. Deming


A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the
Department of Epidemiology, School of Public Health.

Chapel Hill
2005


Approved by:



Advisor: Professor Robert C. Millikan




Reader: Professor Andrew F. Olshan



Reader: Professor Jane C. Schroeder



Reader: Professor Michael Symons



Reader: Professor Leigh Thorne

TABLE OF CONTENTS

	Page
LIST OF TABLES.....	xi
LIST OF FIGURES.....	xv
LIST OF ABBREVIATIONS.....	xvi
CHAPTER	
I. BACKGROUND	
Introduction.....	1
Literature Review.....	1
Public health significance.....	1
Breast cancer heterogeneity and classification.....	2
Risk factors for breast cancer.....	5
Prognostic factors for breast cancer.....	17
E-cadherin: Structure and general description.....	21
E-cadherin in the estrogen/breast cancer hypothesis.....	22
-160 C.A SNP in the e-cadherin gene.....	24
E-cadherin expression in breast tissue and breast cancer.....	28
References.....	38
Tables and figures.....	56

II.	STUDY DESIGN AND METHODS.....	57
	Summary of study.....	58
	Specific aims.....	60
	Materials and methods.....	63
	Description of study population: The Carolina Breast Cancer Study.....	64
	Data collection.....	65
	Laboratory methods.....	67
	Data analysis.....	71
	Power calculations.....	80
	Reliability results.....	86
	References.....	88
	Tables and figures.....	101
III.	RESULTS: E-CADHERIN EXPRESSION, CDH1 GENOTYPE AND RISK OF BREAST CANCER.....	105
	Statistical analysis.....	105
	Evaluating potential selection bias.....	107
	E-cadherin and risk of breast cancer.....	110
	<i>CDH1</i> polymorphism frequencies.....	112
	ORs for breast cancer and <i>CDH1</i> genotype.....	113
	<i>CDH1</i> genotype and e-cadherin tumor expression.....	114
	References.....	114
	Tables and figures.....	118
IV.	RESULTS: E-CADHERIN EXPRESSION, CDH1 GENOTYPE AND SURVIVAL.....	144

Determination of death.....	144
Survival time.....	145
Censoring status.....	145
Kaplan Meier Survival Analysis.....	146
Survival over entire period of observation.....	146
Five year survival.....	146
Demographic and tumor characteristics and survival.....	147
E-cadherin protein expression and breast cancer survival.....	149
CDH1 -160 SNP and breast cancer survival.....	150
Missing Values.....	151
Cox proportional hazards analysis.....	152
All-cause mortality vs. breast cancer mortality.....	152
Evaluation of proportional hazards assumption.....	152
Identification of potential confounders.....	154
Evaluation of potential covariate interactions with e-cadherin Protein expression and <i>CDH1</i> genotype.....	156
Independent prognostic value of e-cadherin protein expression in breast cancer mortality.....	157
E-cadherin and lymph node status.....	158
Independent prognostic value of the CDH1 -160 C/A genotype in breast cancer mortality.....	158
References.....	160
Tables and figures.....	161
V. DISCUSSION AND SUMMARY.....	194

E-cadherin expression, <i>CDHI</i> genotype, and risk of breast cancer.....	194
Risk factors and e-cadherin defined breast cancer.....	194
<i>CDHI</i> genotype and e-cadherin tumor expression.....	196
<i>CDHI</i> genotype and risk of breast cancer.....	198
Summary of e-cadherin expression, <i>CDHI</i> genotype and risk of breast cancer.....	200
E-cadherin expression, <i>CDHI</i> genotype, and survival.....	202
e-cadherin expression and survival.....	202
<i>CDHI</i> genotype and survival.....	202
Survival summary discussion.....	204
Public health significance.....	207
Future directions.....	208
Conclusions.....	210
References.....	212

LIST OF TABLES

Table 2.1	Response rates of CBCS (Phase I): IHC portion of study.....	102
Table 2.2	Response rate of CBCS cases and controls (Phase I, II and CIS); Genotype portion of study.....	103
Table 2.3	Tumor block retrieval rates.....	104
Table 2.4	Power to detect and association among the different subgroups given various prevalence of exposures.....	105
Table 2.5	Power to detect a gene environment interaction.....	106
Table 2.6	Power to detect a gene environment interaction.....	107
Table 2.7a	E-cadherin intra-rater reliability scoring results: Overall e-cadherin positivity.....	108
Table 2.7b	E-cadherin intra-rater reliability scoring results: Intensity.....	108
Table 2.7c	E-cadherin intra-rater reliability scoring results: Percent cells positive.....	108
Table 2.7d	E-cadherin intra-rater reliability scoring results: Cellular localization.....	109
Table 2.7e	E-cadherin intra-rater reliability scoring results: Distribution.....	109
Table 2.7f	E-cadherin intra-rater reliability scoring results: Pattern.....	109
Table 2.8	E-cadherin tumor positivity by scorer.....	110
Table 2.9a	Overall e-cadherin positivity by scorer: (SD vs. DC).....	111
Table 2.9b	Overall e-cadherin positivity by scorer: (SD vs. LT).....	111
Table 2.9c	Overall e-cadherin positivity by scorer: (DC vs. LT).....	111
Table 2.10a	Intensity of e-cadherin staining by scorer: (SD vs. DC).....	112
Table 2.10b	Intensity of e-cadherin staining by scorer: (SD vs. LT).....	112
Table 2.10c	Intensity of e-cadherin staining by scorer: (DC vs. LT).....	112
Table 2.11a	Percent of cells positive by scorer: (SD vs. DC).....	113

Table 2.11b	Percent of cells positive by scorer: (SD vs. LT).....	113
Table 2.11c	Percent of cells positive by scorer: (DC vs. LT).....	113
Table 2.12	Inter-rater reliability of other e-cadherin scoring parameters.....	114
Table 2.13	Summary of tumor sections available for staining.....	115
Table 3.1	Comparison of characteristics of cases with and without e-cadherin protein expression information.....	132
Table 3.2	Distribution of <i>CDHI</i> genotype by various demographic characteristics among CBCS phase I and II controls.....	135
Table 3.3	Comparison of characteristics of cases with and without <i>CDHI</i> genotype information among CBCS phase I and II cases.....	137
Table 3.4	Odds ratios for breast cancer in relation to various known and Suspected risk factors in CBCS.....	140
Table 3.5	Distribution of e-cadherin expression by various demographic and tumor characteristics among CBCS participants.....	142
Table 3.6	Odds ratios and 95% confidence intervals for e-cadherin+ and e-cadherin-controls in CBCS.....	145
Table 3.7	Odds ratios and 95% confidence intervals for e-cadherin + and e-cadherin- versus controls in CBCS individually adjusted for ER status, PR status, or stage.....	149
Table 3.8	<i>CHDI</i> allele frequencies among cases and controls with <i>CDHI</i> genotype Information.....	151
Table 3.9	Distributions and odds ratios for <i>CDHI</i> genotype among cases and controls with <i>CDHI</i> genotype information and test for Hardy Weinberg information.....	152
Table 3.10	Odds ratios for breast cancer cases versus controls by <i>CDHI</i> genotype.....	153
Table 3.11a	P-values for potential interactions between <i>CDHI</i> genotype and various estrogen-related covariates in overall odds of breast cancer.....	154
Table 3.11b	Odds ratios for potential interactions between <i>CDHI</i> genotype and oral contraceptive use, hormone replacement therapy use, and age at menarche in all breast cancer.....	154

Table 3.12a	Distribution of e-cadherin protein expression by <i>CDHI</i> genotype.....	155
Table 3.12b	Distributions of e-cadherin protein expression by <i>CDHI</i> genotype Based on 8-level categorization.....	155
Table 3.13	Distributions and odds ratio for <i>CDHI</i> genotype and e-cadherin + and e-cadherin – breast cancer.....	156
Table 3.14a	P-values for potential interactions between <i>CDHI</i> genotype and various estrogen-related covariates in e-cadherin delineated breast cancer.....	157
Table 3.14b	P-values for potential interactions between <i>CDHI</i> genotype and oral Contraceptive use and parity in e-cadherin delineated breast cancer.....	157
Table 4.1	Summary of classification of event and censoring date for various subgroups utilized in the survival analysis.....	175
Table 4.2	Number of individuals having event or being censored in various analytic subgroups.....	176
Table 4.3	5-year and entire period of observation all-cause survival by demographic characteristics in patients with invasive breast cancer.....	177
Table 4.4a	5-year and entire period of observation breast cancer-specific survival by demographic characteristics in patients with invasive breast carcinoma.....	178
Table 4.4b	Joint effects of race and menopausal status on survival over entire period of observation.....	179
Table 4.5	5-year and entire period of observation all-cause survival by tumor characteristics in patients with invasive breast carcinoma.....	180
Table 4.6	5-year and entire period of observation breast cancer-specific survival by tumor characteristics in patients with invasive breast cancer.....	182
Table 4.7a	5-year and entire period of observation all-cause survival based on e-cadherin status in various subgroups in patients with invasive breast carcinoma.....	184
Table 4.8	5-year and entire period of observation breast cancer-specific survival based on e-cadherin status in various subtypes.....	186
Table 4.8b	Joint effect of e-cadherin expression and estrogen receptor status on survival over entire period of observation.....	185

Table 4.9	5-year and entire period of observation all-cause survival based on <i>CDHI</i> genotype.....	187
Table 4.10	5-year and entire period of observation breast cancer-specific survival based on <i>CDHI</i> genotype.....	188
Table 4.11	Univariate hazard ratios and 95% confidence intervals for various Factors for the entire period of observation.....	189
Table 4.12	Preliminary assessment of confounding with e-cadherin protein expression among breast cancer deaths (5-year follow-up).....	191
Table 4.13	Preliminary assess of confounding with e-cadherin protein expression among breast cancer deaths (entire period of follow-up).....	192
Table 4.14	Preliminary assessment of confounding with <i>CDHI</i> genotype among breast cancer deaths (5-year follow-up).....	193
Table 4.15	Preliminary assessment of confounding with <i>CDHI</i> genotype among breast cancer deaths (entire period of observations).....	194
Table 4.16	P-values for potential interactions between e-cadherin expression and various covariates.....	195
Table 4.17	P-values for potential interactions between <i>CDHI</i> genotype and various covariates.....	196
Table 4.18	5-year and entire period of observation Cox proportional hazard ratios for breast cancer deaths based on e-cadherin tumor expression.....	197
Table 4.19	5-year and entire period of observation Cox proportional hazard ratios for breast cancer deaths based on e-cadherin tumor expression stratified by lymph node status.....	198
Table 4.20	5-year and entire period of observation Cox proportional hazard ratios for breast cancer deaths based on <i>CDHI</i> genotype.....	199
Table 4.21	5-year and entire period of observation Cox proportional hazard ratios for breast cancer deaths based on <i>CDHI</i> genotype stratified by P53 functional mutation status.....	200

LIST OF FIGURES

Figure 1.1	E-cadherin and its relationship to other cellular proteins.....	56
Figure 1.2	Model of factors and presumed mechanisms involved in the estrogen and e-cadherin pathway.....	57
Figure 2.1	Examples of e-cadherin immunohistochemical staining in normal Breast tissue, ductal carcinoma <i>in situ</i> , and invasive lobular and invasive ductal breast cancer.....	117
Figure 2.2	Scoring sheet: e-cadherin expressin in tumors of Phase I Carolina Breast Cancer Study.....	118
Figure 4.1	5-year breast cancer-specific survival by e-cadherin tumor expression status.....	201
Figure 4.2	Entire period of observation breast cancer-specific survival by e-cadherin tumor expression status.....	202
Figure 4.3	5-year breast cancer-specific survival by <i>CDHI</i> genotype.....	203
Figure 4.4	5-year breast cancer-specific survival by e-cadherin tumor expression status with missing data plotted.....	204
Figure 4.5	5-year breast cancer-specific survival by <i>CDHI</i> genotype with missing data plotted.....	205
Figure 4.6	log-log plot of months survived versus the survival distribution function for e-cadherin tumor expression to assess proportional hazards assumption.....	206
Figure 4.7	log-log plot of months survived versus the survival distribution function for <i>CDHI</i> genotype to assess proportional hazards assumption....	207